DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Clinical trial NCT06221748 · RECRUITING
Trial details
- NCT number
- NCT06221748
- Sponsor
- RemeGen Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-22
- Primary completion
- 2026-12-01
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.